You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD30

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin Lymphoma, Adult Trial in Chapel Hill (ATLCAR.CD30, Bendamustine, Fludarabine)

No longer available
  • Hodgkin Lymphoma, Adult
  • ATLCAR.CD30
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2021

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 cells)

Active, not recruiting
  • Hodgkin Disease
  • +8 more
  • ATLCAR.CD30 cells
  • Chapel Hill, North Carolina
  • +1 more
Mar 2, 2022

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Recurrent Classic Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Nivolumab)

Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Brentuximab Vedotin
  • Nivolumab
  • Duarte, California
    City of Hope Medical Center
Feb 16, 2022

NK/T Cell Lymphoma Nos Trial (Brentuximab Vedotin in Combination with Tislelizumab)

Not yet recruiting
  • NK/T Cell Lymphoma Nos
  • Brentuximab Vedotin in Combination with Tislelizumab
  • (no location specified)
Apr 6, 2022

Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +9 more
  • Anti-CD30/CD16A Monoclonal Antibody AFM13
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic

Active, not recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022

Lymphatic Diseases Trial in Italy (Brentuximab Vedotin)

Completed
  • Lymphatic Diseases
  • Brentuximab Vedotin
  • Bologna, Italy
  • +3 more
Mar 21, 2022

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab

Recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Bendamustine Hydrochloride
  • Brentuximab Vedotin
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Dec 17, 2021

Brentuximab Vedotin in Pediatric Hodgkin Lymphoma

Not yet recruiting
  • Hodgkin Lymphoma
  • Brentuximab Vedotin
  • (no location specified)
Jul 28, 2022

HIV Infection, HIV-associated Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma Trial in France (brentuximab vedotin,

Active, not recruiting
  • HIV Infection
  • +3 more
  • brentuximab vedotin
  • +3 more
  • Clamart, France
  • +5 more
Aug 11, 2022

T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)

Not yet recruiting
  • T-Cell Lymphoma
  • (no location specified)
Jul 22, 2022

Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

Recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
Jun 15, 2022

Lymphoma Trial in Berne (Brentuximab Vedotin, BeEAM Regimen)

Recruiting
  • Lymphoma
  • Brentuximab Vedotin
  • BeEAM Regimen
  • Berne, Switzerland
    Department for Medical Oncology University Hospital/Inselspital
Feb 4, 2022

Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other,

Active, not recruiting
  • Classic Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin
  • +2 more
  • Duarte, California
  • +5 more
Mar 17, 2022

Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)

Not yet recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +13 more
  • (no location specified)
Feb 2, 2023

Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in United

Active, not recruiting
Has Results
  • Ann Arbor Stage IB Hodgkin Lymphoma
  • +10 more
  • Brentuximab Vedotin
  • Nivolumab
  • Palo Alto, California
  • +8 more
Jul 20, 2022

A Study of Chinese Adults With Lymphoma

Recruiting
  • Lymphoma
    • Beijing, Beijing, China
    • +18 more
    Nov 3, 2022

    Leukemia Trial in Houston (Brentuximab Vedotin, 5-Azacytidine)

    Terminated
    Has Results
    • Leukemia
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Sep 7, 2022

    Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in United States (brentuximab vedotin)

    Terminated
    • Hodgkin Lymphoma
    • +2 more
    • brentuximab vedotin
    • Anaheim, California
    • +18 more
    Dec 6, 2022

    CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive DLBCL, CD30-Positive Gray Zone Lymphoma Trial in

    Completed
    Has Results
    • CD30 Positive Primary Mediastinal Large B-cell Lymphoma
    • +2 more
    • brentuximab vedotin
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Dec 14, 2020

    Relapsed or Refractory CD30+ Malignancies When Re-treated With

    Completed
    • Hodgkin Disease
    • Lymphoma, T-Cell, Cutaneous
    • No Intervention
    • San Bartolome, Alicante, Spain
    • +29 more
    Jul 28, 2022

    Lymphatic Diseases Trial in Italy (Brentuximab Vedotin, Bendamustine)

    Terminated
    • Lymphatic Diseases
    • Bologna, BO, Italy
    • +4 more
    May 26, 2021

    Brentuximab Vedotin in Adults With CD30-positive Lymphoma

    Recruiting
    • Lymphoma
    • No Intervention
    • Hefei, Anhui, China
    • +25 more
    Jul 14, 2022

    Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

    Not yet recruiting
    • Cancer
    • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
    • Fludarabine (30 mg/m^2)
    • +2 more
    • (no location specified)
    Jul 25, 2023